• Profile
Close

Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5, or 6

Journal of Viral Hepatitis May 24, 2019

Lawitz E, et al. - Given the suboptimal effectiveness of the two-drug combination of ruzasvir 60 mg plus uprifosbuvir 450 mg in certain hepatitis C virus (HCV) genotypes in a phase 3 clinical trial, researchers examined rusasvir in combination with uprifosbuvir given at a higher dose for effectiveness and safety. Treatment-naive or interferon (with or without ribavirin)–experienced patients with or without compensated cirrhosis were administered ruzasvir 180 mg plus uprifosbuvir 450 mg once daily for 12 weeks. Outcomes revealed the high efficacy of the two-drug combination of ruzasvir 180 mg plus uprifosbuvir 450 mg for 12 weeks in participants infected with HCV GT1, GT2, GT4, GT5, and GT6, but a lower efficacy in GT3-infected persons. The regimen was considered to be well-tolerated.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay